Lending a helping hand, screening chemical libraries for compounds that enhance β-hexosaminidase A activity in GM2 gangliosidosis cells

FEBS Journal

Volumn 274, Issue 19, 2007, Pages 4951-4961

  Tropak, Michael B ^a   Mahuran, Don ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Active site specific chaperones; Enzyme enhancement therapy; Hexosaminidase; High throughput screening; Lysosomal; Pharmacological chaperones; Post translational regulation; Sandhoff; Subunit assembly; Tay Sachs

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE A; ENZYME INHIBITOR; GANGLIOSIDE GM2; N ACETYLGLUCOSAMINE THIAZOLINE; PYRIMETHAMINE; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME STRUCTURE; FOOD AND DRUG ADMINISTRATION; GANGLIOSIDOSIS; GENE MUTATION; HUMAN; LYSOSOME STORAGE DISEASE; NONHUMAN; PRIORITY JOURNAL; SANDHOFF DISEASE; SCREENING; SHORT SURVEY; TAY SACHS DISEASE;

BETA-N-ACETYLHEXOSAMINIDASES; ENZYME INHIBITORS; GANGLIOSIDOSES, GM2; HUMANS; MODELS, MOLECULAR;

EID: 34748843178     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2007.06040.x     Document Type: Short Survey

References (47)

1. Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochim Biophys Acta 1455, 105 138.
2. Leinekugel P, Michel S, Conzelmann E Sandhoff K (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88, 513 523.
3. Mark B, Mahuran DJ, Cherney MM, Zhao D, Knapp S James MNG (2003) Crystal structure of human β-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease. J Mol Biol 327, 1093 1109.
4. Lemieux MJ, Mark BL, Cherney MM, Withers SG, Mahuran DJ James MN (2006) Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of G(M2) ganglioside hydrolysis. J Mol Biol 359, 913 929.
5. Mahuran DJ (1998) The GM2 activator protein, its roles as a co-factor in GM2 hydrolysis and as a general glycolipid transport protein. Biochim Biophys Acta 1393, 1 18.
6. Wright CS, Li SC Rastinejad F (2000) Crystal structure of human GM2-activator protein with a novel beta-cup topology. J Mol Biol 304, 411 422.
7. Sharma R, Bukovac S, Callahan J Mahuran D (2003) A single site in human β-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside. Biochim Biophys Acta 1637, 113 118.
8. Sharma R, Deng H, Leung A Mahuran D (2001) Identification of the 6-sulfate binding site unique to α-subunit-containing isozymes of human β-hexosaminidase. Biochemistry 40, 5440 5446.
9. M2 gangliosidosis). J Biol Chem 261, 12680 12685.
10. Korneluk RG, Mahuran DJ, Neote K, Klavins MH, O'Dowd BF, Tropak M, Willard HF, Anderson MJ, Lowden JA Gravel RA (1986) Isolation of cDNA clones coding for the alpha-subunit of human beta-hexosaminidase. Extensive homology between the alpha- and beta-subunits and studies on Tay-Sachs disease. J Biol Chem 261, 8407 8413.
11. Hasilik A Neufeld EF (1980) Biosynthesis of lysosomal enzymes in fibroblasts: synthesis as precursors of higher molecular weight. J Biol Chem 255, 4937 4945.
12. Proia RL, d'Azzo A Neufeld EF (1984) Association of alpha- and beta-subunits during the biosynthesis of beta-hexosaminidase in cultured human fibroblasts. J Biol Chem 259, 3350 3354.
13. Hurtley SM Helenius A (1989) Protein oligomerization in the endoplasmic reticulum. Ann Rev Cell Biol 5, 277 307.
14. M2 gangliosidosis patients share a common genetic defect. Am J Hum Genet 46, 817 821.
15. d'Azzo A, Proia RL, Kolodny EH, Kaback MM Neufeld EF (1984) Faulty association of alpha- and beta-subunits in some forms of beta-hexosaminidase A deficiency. J Biol Chem 259, 11070 11074.
16. Brown CA Mahuran DJ (1993) beta-Hexosaminidase isozymes from cells cotransfected with alpha and beta cDNA constructs: analysis of the alpha-subunit missense mutation associated with the adult form of Tay-Sachs disease. Am J Hum Genet 53, 497 508.
17. Dill KD Shortle D (1991) Denatured states of proteins. Annu Rev Biochem 60, 795 825.
18. Edgington SM (1992) Rites of passage: Moving biotech proteins through the ER. Biotechnology 10, 1413 1420.
19. Alber T (1989) Mutational effects on protein stability. Annu Rev Biochem 58, 765 798.
20. Conn PM, Knollman PE, Brothers SP Janovick JA (2006) Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor. Mol Endocrinol 20, 3035 3041.
21. Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, Changeux JP Corringer PJ (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 46, 595 607.
22. Corringer PJ, Sallette J Changeux JP (2006) Nicotine enhances intracellular nicotinic receptor maturation: a novel mechanism of neural plasticity? J Physiol Paris 99, 162 171.
23. Van Craenenbroeck K, Gellynck E, Lintermans B, Leysen JE, Van Tol HH, Haegeman G Vanhoenacker P (2006) Influence of the antipsychotic drug pipamperone on the expression of the dopamine D4 receptor. Life Sci 80, 74 81.
24. Van Craenenbroeck K, Clark SD, Cox MJ, Oak JN, Liu F Van Tol HH (2005) Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem 280, 19350 19357.
25. Trefz FK, Scheible D, Frauendienst-Egger G, Korall H Blau N (2005) Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterin. Mol Genet Metab 86 (Suppl. 1 S75 S80.
26. Aguado C, Perez B, Ugarte M Desviat LR (2006) Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells. FEBS Lett 580, 1697 1701.
27. Perez B, Desviat LR, Gomez-Puertas P, Martinez A, Stevens RC Ugarte M (2005) Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol Genet Metab 86 (Suppl. 1 S11 S16.
28. Sawkar AR, Adamski-Werner SL, Cheng WC, Wong CH, Beutler E, Zimmer KP Kelly JW (2005) Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles. Chem Biol 12, 1235 1244.
29. Tropak MB, Reid SP, Guiral M, Withers SG Mahuran D (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients. J Biol Chem 279, 13478 13487.
30. Tropak MB, Blanchard JE, Withers SG, Brown ED Mahuran D (2007) High-throughput screening for human lysosomal beta-N-acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol 14, 153 164.
31. Villalona-Calero MA, Eder JP, Toppmeyer DL, Allen LF, Fram R, Velagapudi R, Myers M, Amato A, Kagen-Hallet K, Razvillas B et al. (2001) Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. J Clin Oncol 19, 857 869.
32. Maegawa GH, Tropak M, Butner J, Stockley T, Kok F, Clarke JT Mahuran DJ (2007) Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 282, 9150 9161.
33. Weiss LM, Harris C, Berger M, Tanowitz HB Wittner M (1988) Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis 157, 580 583.
34. Leport C, Chene G, Morlat P, Luft BJ, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon R et al. (1996) Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis 173, 91 97.
35. Weiss LM, Luft BJ, Tanowitz HB Wittner M (1992) Pyrimethamine concentrations in serum during treatment of acute murine experimental toxoplasmosis. Am J Trop Med Hyg 46, 288 291.
36. Buxton ILO (2006) Pharmacokinetics and pharmacodynamics: the dymamics of drug absorption, distribution, action and elimination. In Goodman and Gilman's the Pharmacological Basis of Therapeutics (LL Brunton ed). McGraw-Hill Books, New York, NY.
37. Desnick RJ Schuchman EH (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 3, 954 966.
38. Fan JQ (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 24, 355 360.
39. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE Kelly JW (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci USA 99, 15428 15433.
40. Arakawa T, Ejima D, Kita Y Tsumoto K (2006) Small molecule pharmacological chaperones: from thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 1764, 1677 1687.
41. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Gorgun CZ Hotamisligil GS (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313, 1137 1140.
42. Navon R, Kopel R, Nutman J, Frisch A, Conzelmann E, Sandhoff K Adam A (1985) Hereditary heat-labile hexosaminidase B: a variant whose homozygotes synthesize a functional hex A. Am J Hum Genet 37, 138 146.
43. Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, Dwek RA Platt FM (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56, 642 649.
44. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H et al. (2006) Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127, 803 815.
45. Bertelsen M (2006) Multiplex analysis of inflammatory signaling pathways using a high-content imaging system. Methods Enzymol 414, 348 363.
46. Fan JQ Ishii S (2003) Cell-based screening of active-site specific chaperone for the treatment of Fabry disease. Methods Enzymol 363, 412 420.
47. Ron I Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14, 2387 2398.